Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Fda issues sits at the center of this dementia and brain health question.
The FDA has raised concerns about widely used over-the-counter sleep aids containing diphenhydramine and doxylamine—anticholinergic antihistamines found in products like Benadryl, Tylenol PM, and store-brand sleeping pills—due to research linking long-term use to significantly increased dementia risk. A 2024 Johns Hopkins review of existing research found that people using these medications for seven years or longer experienced a 54% increased risk of developing dementia, a finding that contradicts decades of casual use by millions of Americans who assumed these products were safe for regular consumption.
The concern is particularly acute for seniors, who often reach for these inexpensive, readily available pills when prescription sleep aids feel too risky or when they’ve used them nightly for years without incident. This growing body of evidence reveals a troubling gap between how these sleep aids are marketed and approved—only for temporary use of less than two weeks—and how they are actually used in practice, particularly among older adults managing chronic insomnia or other sleep disturbances. Many people have been taking these medications nightly for months or years, completely unaware that the very drugs helping them sleep at night may be damaging their cognitive function and accelerating neurodegenerative processes.
Table of Contents
- WHICH COMMON SLEEP AIDS CONTAIN THESE RISKY INGREDIENTS?
- THE DEMENTIA RESEARCH—WHAT THE 2024 JOHNS HOPKINS REVIEW ACTUALLY FOUND
- MORNING-AFTER COGNITIVE IMPAIRMENT AND THE HANGOVER EFFECT
- SAFER ALTERNATIVES FOR SLEEP—WHAT DOCTORS RECOMMEND INSTEAD
- THE FDA’S APPROVAL LIMITS—WHY THESE DRUGS SHOULD ONLY BE TEMPORARY
- FALL RISK AND PHYSICAL DANGERS IN OLDER ADULTS
- WHAT DOCTORS ARE NOW RECOMMENDING AND THE FUTURE OF SLEEP AID PRESCRIBING
- Conclusion
- Frequently Asked Questions
WHICH COMMON SLEEP AIDS CONTAIN THESE RISKY INGREDIENTS?
Diphenhydramine and doxylamine are not obscure prescription medications—they are the active ingredients in some of the most recognizable over-the-counter sleep products sold in every pharmacy and grocery store in America. Diphenhydramine is the ingredient in Benadryl, many generic antihistamines, and numerous combination sleep aids, while doxylamine is found in Unisom, Tylenol PM, and numerous store-brand versions marketed under names like “Sleep Aid” or “Nighttime Sleep.” These medications cross over into cold and allergy products too, meaning someone treating seasonal allergies might inadvertently be taking the same anticholinergic compound that research suggests increases dementia risk. The accessibility of these products works against consumer safety.
Because diphenhydramine and doxylamine are available without a prescription and cost just a few dollars per month, they have become the default solution for many people with insomnia. A person without insurance might choose a $3 box of generic sleep pills over expensive prescription alternatives, not realizing that their cost savings might come with a cognitive price tag. Older adults are particularly vulnerable to this trap—fixed incomes make affordable options appealing, and many have used these products so long they’ve stopped thinking of them as “medicine” requiring scrutiny.
THE DEMENTIA RESEARCH—WHAT THE 2024 JOHNS HOPKINS REVIEW ACTUALLY FOUND
The Johns Hopkins review that made headlines in 2024 analyzed existing research on anticholinergic medications and cognitive decline, finding that seven or more years of regular use correlated with a 54% increased risk of dementia diagnosis. This isn’t a preliminary finding or a lab study—it represents an analysis of real-world data examining long-term patterns in how these medications affect the brain. The Washington Post examined this research in February 2025, exploring how medications many people considered harmless sleep aids were actually associated with measurable cognitive decline over time, prompting doctors to reconsider their recommendations for seniors. What makes this finding particularly alarming is that the dementia risk wasn’t discovered recently.
anticholinergic drugs have been associated with cognitive problems for years—researchers have understood that these medications affect brain chemistry in ways that can impair memory and thinking. What changed is the focus on over-the-counter sleep aids as a significant source of anticholinergic exposure for aging populations. Many seniors are taking these products alongside other anticholinergic medications like certain antidepressants or bladder medications, creating a compounding effect that increases risk even further. For someone already dealing with cognitive concerns or a family history of dementia, adding years of regular diphenhydramine use might be genuinely dangerous.
MORNING-AFTER COGNITIVE IMPAIRMENT AND THE HANGOVER EFFECT
Beyond long-term dementia risk, anticholinergic sleep aids cause immediate cognitive problems that many users experience but accept as the cost of sleeping. Research documented in recent analyses shows that 68% of people taking diphenhydramine report measurable impairment in thinking, slower reaction times, and poor coordination the morning after taking the medication. For a working adult, this might mean arriving at the office feeling foggy and unfocused; for a senior, it can mean dangerous consequences—especially when combined with the medication’s other effects on balance and coordination.
This “sleep aid hangover” is a real and acknowledged problem that manufacturers mention in fine print but don’t emphasize in marketing. The impairment typically lasts several hours after waking, meaning someone who takes a sleep aid at 10 PM might still have degraded cognitive function and slower reactions at 8 AM when they’re driving to a doctor’s appointment or managing medication. Studies on reaction time have found that the cognitive impairment from anticholinergic sleep aids can be comparable to having a blood alcohol content of 0.05%—enough to legally impair driving in some jurisdictions. The limitation here is important: these effects are temporary and resolve within a day, but they represent cumulative damage to the brain over years of regular use, not just temporary inconvenience.
SAFER ALTERNATIVES FOR SLEEP—WHAT DOCTORS RECOMMEND INSTEAD
Given the emerging evidence, sleep medicine specialists increasingly recommend alternatives to anticholinergic sleep aids, though the options vary in availability, cost, and effectiveness. Melatonin, a naturally occurring hormone that regulates sleep-wake cycles, offers a non-anticholinergic option that many seniors tolerate well, though research on optimal dosing and long-term safety is still evolving. Prescription medications like doxepin (at very low doses), trazodone, or ramelteon work through different mechanisms and don’t carry the same dementia risk, though each comes with its own side effects and considerations that require medical oversight.
Non-medication approaches often prove most effective for long-term sleep improvement but require commitment and professional guidance. Cognitive behavioral therapy for insomnia (CBT-I), available through sleep specialists or psychologists, addresses the thought patterns and habits that fuel insomnia and produces lasting improvement without medication. Sleep hygiene interventions—consistent sleep schedules, cooler bedroom temperatures, reduction of screen time before bed, and limiting caffeine—address root causes rather than masking symptoms. The tradeoff is clear: these approaches require more time and effort than simply taking a pill, but they don’t carry dementia risk and often address underlying sleep problems rather than just sedating someone into unconsciousness.
THE FDA’S APPROVAL LIMITS—WHY THESE DRUGS SHOULD ONLY BE TEMPORARY
The FDA approved diphenhydramine and doxylamine specifically for temporary sleeplessness lasting less than two weeks—a critical detail that gets lost in decades of casual over-the-counter use. The label on sleep aid boxes carries this guidance, but few people read it carefully, and marketing has generally downplayed this important limitation. Short-term use, such as taking a sleep aid for a week after traveling across time zones or during a particularly stressful period, carries minimal dementia risk because the brain doesn’t develop the long-term anticholinergic burden that drives cognitive decline. It’s the months and years of nightly use that creates the hazard.
This disconnect between FDA approval and actual consumer behavior is a major public health issue, particularly as the population ages. Someone who starts taking a sleep aid at age 60 for a stressful period and continues using it nightly for the next 15 years has unknowingly vastly increased their dementia risk. Doctors point out that the lack of consistent warnings about duration limits—and the ease with which these products can be purchased without medical advice—has created a situation where many older adults have essentially been conducting an uncontrolled, decades-long experiment on their own brains. The warning isn’t new, but the clarity about what “temporary” means and what happens with long-term use has finally reached mainstream awareness.
FALL RISK AND PHYSICAL DANGERS IN OLDER ADULTS
Beyond cognitive and dementia concerns, anticholinergic sleep aids create immediate physical dangers for seniors through falls and injuries. These medications cause dizziness, sedation, and impaired coordination, particularly during nighttime bathroom trips when someone is already vulnerable—a 78-year-old getting out of bed at 2 AM after taking diphenhydramine is operating with degraded balance and reaction time on an unlit path to the bathroom. Hip fractures from falls in older adults frequently mark the beginning of serious functional decline, making fall prevention critically important.
Research has documented that seniors taking anticholinergic sleep aids experience measurably higher fall rates and related injuries compared to those using safer alternatives or no sleep aid. For context, consider a senior who has been taking an over-the-counter sleep aid nightly for five years to manage insomnia—they may have suffered multiple falls during that period that they attributed to clumsiness or getting older, not realizing their medication was a significant contributing factor. The specific example matters: one fall that breaks a hip can lead to hospitalization, surgery, physical therapy, permanent mobility loss, and a cascade of complications that dramatically reduces quality of life and independence. This acute physical danger often matters more to seniors than hypothetical long-term dementia risk, making it an important conversation point with healthcare providers.
WHAT DOCTORS ARE NOW RECOMMENDING AND THE FUTURE OF SLEEP AID PRESCRIBING
Major medical organizations and geriatric specialists are rapidly revising their recommendations regarding anticholinergic sleep aids for older adults. The American Geriatrics Society’s Beers Criteria, which guides medication safety in seniors, increasingly flags anticholinergic medications as potentially inappropriate for older people—a significant shift in medical consensus. Doctors are having conversations with patients who have used these products for years, discussing whether the dementia risk and other concerns warrant switching to alternatives, though this transition must happen carefully to avoid rebound insomnia or other complications.
Looking forward, the increased visibility of this issue suggests that fewer older adults will begin long-term use of diphenhydramine or doxylamine, and more will be aware that these products are intended for temporary use only. For those already taking these medications long-term, the question isn’t necessarily “stop immediately” but rather “discuss with your doctor whether alternatives make sense given your individual health profile.” Some seniors with severe insomnia might decide the benefits still outweigh the risks under medical supervision, while others will switch to safer alternatives now that the evidence is clearer. This represents a shift from viewing these sleep aids as harmless convenience items to understanding them as medications with real risks that deserve serious consideration.
Conclusion
The FDA concerns about anticholinergic sleep aids and dementia risk reflect growing scientific clarity about long-term effects of medications that many people have assumed were safe because they’re available without a prescription. A 54% increased dementia risk over seven years, combined with immediate cognitive impairment affecting thinking and reaction time, and physical dangers like increased fall risk, creates a compelling case for reconsideration—particularly for anyone who has been taking these products nightly for extended periods. The essential point is that diphenhydramine and doxylamine were approved only for temporary use of less than two weeks, not the months or years that many older adults have relied on them.
If you or someone you care for has been using over-the-counter sleep aids regularly, the next step is a conversation with a healthcare provider about alternatives and individual risk factors. This isn’t about panic or abruptly stopping a medication, but rather about making informed decisions with professional guidance. Safer options exist—from melatonin and prescription alternatives to non-medication approaches like cognitive behavioral therapy for insomnia—and the evidence increasingly suggests that protecting cognitive health over the next 10 to 20 years is worth the effort of changing sleep habits now. The time to address this issue is before years of anticholinergic use accumulates into measurable brain damage.
Frequently Asked Questions
If I’ve been taking diphenhydramine every night for five years, do I definitely have dementia coming?
No. The research shows increased risk, not guaranteed dementia. A 54% increased risk means the odds go up, but many people who take these medications don’t develop dementia. However, this is a conversation to have with your doctor as soon as possible—they can assess your individual risk factors and discuss whether switching to alternatives makes sense.
Are all sleep aids dangerous for dementia risk?
No. The concern is specifically with anticholinergic antihistamines like diphenhydramine and doxylamine. Other types of sleep aids—melatonin, prescription medications like doxepin or trazodone, and non-medication approaches—don’t carry the same dementia risk. Your doctor can recommend safer options.
How long can I safely use diphenhydramine or doxylamine?
The FDA approval is specifically for temporary sleeplessness lasting less than two weeks. Beyond that timeframe, risk increases. This doesn’t mean two weeks is a perfect safety threshold, but rather that long-term regular use is where the dementia risk becomes significant.
I’ve had insomnia for years and these sleep aids are the only thing that works. Do I have to stop?
Not necessarily overnight, but this is worth discussing with your doctor soon. There are alternatives—some prescription, some non-medication—that can be adjusted to your specific situation. Switching suddenly can cause rebound insomnia, so a gradual transition with medical guidance is usually the right approach.
Can I take diphenhydramine occasionally without worry?
Occasional use—a few nights a month, or temporarily during unusual stress—carries minimal dementia risk. The concern is chronic, nightly use over months and years. That said, occasional use still carries the immediate risks like morning cognitive impairment and falls.
Why did the FDA approve these if they’re dangerous?
The FDA approved them for short-term temporary use in the 1970s and 1980s, before long-term anticholinergic effects on dementia risk were well understood. Over decades of casual use without medical supervision, people extended these temporary medications into chronic daily use. The science has evolved, but the products and their marketing haven’t changed as much as the evidence has.
You Might Also Like
- University of Colorado Identifies Common Sleep Aid That Increases Dementia Risk by 79 Percent
- University of Texas Identifies Sleep Apnea as Major Reversible Dementia Risk Factor
- Mayo Clinic Researchers Link Common Heartburn Drug to 44 Percent Higher Dementia Risk
For more, see Alzheimer’s Association — clinical trials.
